Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …

Background We describe a randomized, non-blinded Phase II interventional study to assess
the safety and efficacy of stereotactic ablative radiotherapy (SABR) for hormone-sensitive …

Objectives To report the outcomes of stereotactic ablative body radiotherapy (SABR) in men
with oligometastatic prostate cancer (PC a) diagnosed on prostate‐specific membrane …

Background The management of oligometastatic prostate cancer (PCa) remains
controversial, especially following the introduction of prostate-specific membrane antigen …

Purpose To assess the outcome of prostate cancer (PCa) patients diagnosed with
oligometastatic disease at recurrence and treated with stereotactic body radiotherapy …

Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment option
for oligometastatic prostate cancer. However, limited prospective evidence is available …

The literature on metastasis-directed therapy for oligometastatic prostate cancer (PCa)
recurrence consists of small heterogeneous studies. This study aimed to reduce the …

Stereotactic body radiotherapy (SBRT) can delay escalation to systemic treatment in men
with oligometastatic prostate cancer (PCa). However, large, prospective studies are still …

Background Previous studies suggested that men with metastatic prostate cancer might
benefit from local treatment of the primary tumor. Objective To determine whether radical …

Background Due to improved imaging sensitivity, the term “oligometastatic” prostate cancer
disease is diagnosed more often, leading to an increasing interest in metastasis-directed …